Transcript What_is_Next_for_Psychopharmacologyx

Where Are
We Heading?
Patricia Brown,
PhD, ARNP
New ADTs This Decade
o
Oleptro (extended release Trazodone) 2010
o
Viibryd (Vilazodone) 2011
o
Fetzima (Levomilnacipran) 2013
o
Brintellix (Vortioxetine) 2013
313 Psychiatric Drugs in
Development
o Dementia (90 Investigational Products)
o Depression (71 Investigational Products )
o Schizophrenia (54 Investigational Products)
o Anxiety Disorders (38 Investigational
Products)
The NIMH Priority for Psychiatric
Drug Development:
o
Rapid acting antidepressant
o
Generation of antipsychotics which assists
with cognition
o
Autism medication which addresses prosocial components
Ketamine infusions
for treatment
resistant depression
ALKS 5461
Blocking the Kappa Receptor
o
When Dynorphin are released=Depression
o
Blocking this stimulates ADT action
o
High levels of Dynorphin block glutamate.
Glutamate is thought to prevent
neuroplasticity and prevent poor learning
abilities and prevent learned helplessness.
 AVP-786
is a modified dextromethorphan
which is an uncompetitive NMDA
receptor antagonist, sigma-1 receptor
agonist and inhibitor of the serotonin
transporter (SERT) and norepinephrine
(NET) transporter
As of Jan 2015 There Are 5
New Anxiety Investigation
Products
o
Most popular drug still are BDZs
o
The goal –to find as efficacious
a drug without the sedative side
effects or addictive potential
Aloradine (PH94B)
o
o
o
A vomeropherine neuroactive
steriod drug
Under development as a nasal
spray formulation
For the acute treatment
of social anxiety disorder in
women.
B-GOS
o
Galacto-oligosaccharides belong to the
group of prebiotics.
o
Prebiotics are defined as non-digestible
food ingredients that beneficially affect
the host by stimulating the growth and/or
activity of beneficial bacteria in the
colon.
IW-2143 (BNC210)
S32212
o
a novel serotonin type 2C receptor inverse
agonist/α2-adrenoceptor antagonist and
potential antidepressant
SL-651,498
o
o
a GABAA receptor agonist with subtypeselective efficacy, as a potential
treatment for generalized anxiety disorder
an anxioselective compound with
functional selectivity for alpha2- and
alpha3-containing gamma-aminobutyric
acid(A) (GABA(A)) receptors.
Translocator Protein (18 kD)
o
Peripheral benzodiazepine
receptor specific ligands
induce microglia functions
consistent with an
activated state.
TMS
Over 30 New Medications in
Development for Schizophrenia
May 2014
Caripazine (RGH-188)
o
D2, D3 antagonist
LY2140023
o
o
Prodrug for an
mGluR2/3 agonist
Phase three
development
Brexpiprazole
OPC-34712
o
a novel D2 dopamine
partial agonist
What is in the works
for Cognition and
social skill
development in
autism
Autism Drugs in Development
o
o
o
o
o
o
o
AT001 ( uoxetine rapid dissolve) ORPHAN DRUG
CM-AT Rye, NY (Fast Track) application
submitted www.curemark.com
CNDO-201 (Trichuris suis ova) Coronado
Biosciences autism Phase II
www.coronadobiosciences.com
Memantine Forest Laboratories Phase II
completed
RG7314 (vasopressin-1 receptor antagonist)
Autism Phase II
Syntocinon nasal spray Retrophin Arbaclofen or
STX209, is a derivative of the FDA-approved
drug, baclofen
NIMH Strategic Objectives
o
o
o
o
Promote discovery in the brain and
behavioral sciences to fuel research on the
causes of mental disorders
Chart mental illness trajectories to determine
when, where and how to intervene
Develop new and better interventions that
incorporate the diverse needs and
circumstances of people with mental illnesses
Strengthen the public health impact of NIMHsupported research
o Thank
You for Your Attention!
References
o
o
Huda Akil, Sydney Brenner, Eric Kandel, Kenneth S.
Kendler, Mary-Claire King, Edward Scolnick, James D.
Watson, and Huda Y. Zoghbi; The Future of Psychiatric
Research: Genomes and Neural Circuits. Science 26
March 2010: 1580-1581.
Steven M. Paul, Daniel S. Mytelka, Christopher T.
Dunwiddie, Charles C. Persinger, Bernard H. Munos,
Stacy R. Lindborg, Aaron L. Schacht ; How to improve
R&D productivity: the pharmaceutical industry's grand
challenge .Nature Reviews Drug Discovery 9, 203-214
(19 February 2010)